Boehringer makes changes to US animal health leadership
Boehringer Ingelheim's president and chief executive of operations in the US will retire at the end of the year, after 15 years at the firm.
Paul Fonteyne is being replaced by Wolfgang Baiker on March 1, 2018. Boehringer's US president and chief executive oversees both human and animal health.
Dr Baiker joined Boehringer in 1989. This is the first time he will work as part of the animal health management team. He has previously served in numerous senior leadership roles across international project management, global development and biopharmaceuticals
Dr Baiker is currently Boehringer's senior vice president of human pharma supply and global quality, as well as head of the biopharma unit.
Until the end of the year, Mr Fonteyne will carry on in a separate role – president of animal health. In this position, he will continue to oversee the integration of operations following the Merial acquisition. Boehringer told Animal Pharm the successor to the position of US president of animal health will be announced at a later time.
Mr Fonteyne has been the head of Boehringer's US operations since 2011. He previously worked for Merck and Abbott Laboratories.
The previous president of animal health in the US was Albrecht Kissel, who recently assumed the role of global head of commercial operations for the animal health business and will be based at the firm's global headquarters in Ingelheim, Germany.
After the Merial merger closed in 2017, Boehringer announced its new management team – drawing from both sides of the transaction.